Blue Jet Healthcare Limited - Asset Resilience Ratio
Blue Jet Healthcare Limited (BLUEJET) has an Asset Resilience Ratio of 13.77% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Blue Jet Healthcare Limited for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Blue Jet Healthcare Limited's Asset Resilience Ratio has changed over time. See BLUEJET total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Blue Jet Healthcare Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see BLUEJET stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs2.10 Billion | 13.77% |
| Total Liquid Assets | Rs2.10 Billion | 13.77% |
Asset Resilience Insights
- Moderate Liquidity: Blue Jet Healthcare Limited has 13.77% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Blue Jet Healthcare Limited Industry Peers by Asset Resilience Ratio
Compare Blue Jet Healthcare Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.21% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.48% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 70.49% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Blue Jet Healthcare Limited (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Blue Jet Healthcare Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 13.17% | Rs1.87 Billion ≈ $20.19 Million |
Rs14.18 Billion ≈ $153.30 Million |
-13.20pp |
| 2024-03-31 | 26.37% | Rs2.79 Billion ≈ $30.20 Million |
Rs10.59 Billion ≈ $114.51 Million |
+4.39pp |
| 2023-03-31 | 21.98% | Rs1.89 Billion ≈ $20.49 Million |
Rs8.62 Billion ≈ $93.23 Million |
+7.11pp |
| 2022-03-31 | 14.87% | Rs1.06 Billion ≈ $11.47 Million |
Rs7.13 Billion ≈ $77.15 Million |
+6.26pp |
| 2021-03-31 | 8.61% | Rs461.64 Million ≈ $4.99 Million |
Rs5.36 Billion ≈ $58.00 Million |
+8.58pp |
| 2020-03-31 | 0.03% | Rs1.10 Million ≈ $11.90K |
Rs3.75 Billion ≈ $40.60 Million |
-- |
About Blue Jet Healthcare Limited
Blue Jet Healthcare Limited engages in the manufacturing and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for use in pharmaceutical and healthcare products. It provides contrast media intermediates; niche pharmaceutical intermediates and APIs; and CDMO/CMO services, as well as end-to-end solutions from process development and commercialization of NCEs, advance… Read more